New Portfolio - New Portfolio

Jason Moore

New Portfolio
Individual Investor
Ranked #348,829 out of 757,311 TipRanks' Investors
Success Rate
34%
35 out of 104
profitable transactions
Average Return
22.61%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▼ 1.18%
6-Month Return▼ 12.95%
12-Month Return-
YTD Return▼ 17.75%
Total Return▼ 17.75%

Best Trade

Opened at
Closed at-
Gain▲ 2734.40%

Bio

Performance

25.76%0-25.76%
▲ 14.08%
▲ 5.22%
▲ 22.18%
Feb 2024
▲ 5.05%
▲ 3.27%
▼ 2.00%
Mar 2024
▼ 12.40%
▼ 4.03%
▼ 13.38%
Apr 2024
▲ 11.46%
▲ 5.06%
▲ 2.86%
May 2024
▼ 2.25%
▲ 3.53%
▼ 4.22%
Jun 2024
▲ 25.76%
▲ 1.21%
▲ 10.90%
Jul 2024
▼ 4.21%
▲ 2.34%
▼ 6.31%
Aug 2024
▲ 2.65%
▼ 0.40%
▼ 1.97%
Sep 2024
TipRanks AverageS&P 500Investor Portfolio
▲ 14.08%▲ 5.22%▲ 22.18%
▲ 5.05%▲ 3.27%▼ 2.00%
▼ 12.40%▼ 4.03%▼ 13.38%
▲ 11.46%▲ 5.06%▲ 2.86%
▼ 2.25%▲ 3.53%▼ 4.22%
▲ 25.76%▲ 1.21%▲ 10.90%
▼ 4.21%▲ 2.34%▼ 6.31%
▲ 2.65%▼ 0.40%▼ 1.97%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Avidity Biosciences
0.97%
▲ 107.97%
1
Open
Mar 08, 2024
Ocuphire Pharma
0.97%
▼ 33.17%
1
Open
Mar 08, 2024
NRX Pharmaceuticals
0.97%
▼ 73.59%
1
Open
Mar 08, 2024
Abeona Therapeutics
0.97%
▼ 31.62%
1
Open
Mar 08, 2024
Cardio Diagnostics Holdings
0.97%
▼ 79.93%
1
Open
Mar 08, 2024
Infobird Co
0.97%
▼ 71.60%
1
Open
Mar 08, 2024
Ocean Biomedical
0.97%
▼ 82.43%
1
Open
Mar 08, 2024
Akebia Therapeutics
0.97%
▼ 8.16%
1
Open
Mar 08, 2024
Agenus
0.97%
▼ 54.85%
1
Open
Mar 08, 2024
Legend Biotech
0.97%
▼ 21.09%
1
Open
Mar 08, 2024
Theratechnologies
0.97%
▼ 0.83%
1
Open
Mar 08, 2024
BeiGene
0.97%
▲ 24.45%
1
Open
Mar 08, 2024
Optinose
0.97%
▼ 49.40%
1
Open
Mar 08, 2024
Supernus Pharmaceuticals
0.97%
▲ 2.48%
1
Open
Mar 08, 2024
Cardiff Oncology
0.97%
▼ 40.58%
1
Open
Mar 08, 2024
Vanda
0.97%
▲ 27.91%
1
Open
Mar 08, 2024
Geron
0.97%
▲ 100.89%
1
Open
Mar 08, 2024
Liquidia Technologies
0.97%
▼ 29.42%
1
Open
Mar 08, 2024
Esperion
0.97%
▼ 20.55%
1
Open
Mar 08, 2024
2seventy bio
0.97%
0.00%
1
Open
Mar 08, 2024